Трансплантация фекальной микробиоты: критерии выбора донора, подготовки и хранения биоматериала
- Авторы: Якупова А.А.1, Абдулхаков С.Р.1,2, Сафин А.Г.1, Алиева И.М.1, Ослопова Ю.В.1, Абдулхаков Р.А.2
-
Учреждения:
- ФГАОУ ВО «Казанский (Приволжский) федеральный университет»
- ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России
- Выпуск: Том 93, № 2 (2021)
- Страницы: 215-221
- Раздел: Обзоры
- URL: https://journals.rcsi.science/0040-3660/article/view/64877
- DOI: https://doi.org/10.26442/00403660.2021.02.200615
- ID: 64877
Цитировать
Полный текст
Аннотация
Трансплантация фекальной микробиоты (ТФМ) – метод лечения, основанный на введении донорского фекального материала реципиенту с целью восстановления нарушенного состава микробиоты кишечника. На сегодняшний день в лечении ряда заболеваний проводятся попытки применения ТФМ. В данном обзоре проведена попытка систематизации имеющихся на сегодняшний день данных, касающихся определения показаний для проведения ТФМ, рекомендаций по отбору доноров, сбору, обработке и хранению донорского биоматериала.
Полный текст
Открыть статью на сайте журналаОб авторах
Алина Айратовна Якупова
ФГАОУ ВО «Казанский (Приволжский) федеральный университет»
Автор, ответственный за переписку.
Email: alinayakupova96@yandex.ru
ORCID iD: 0000-0003-3347-5283
врач-ординатор каф. фундаментальных основ клинической медицины Института фундаментальной медицины и биологии ФГАОУ ВО КФУ
Россия, КазаньСайяр Рустамович Абдулхаков
ФГАОУ ВО «Казанский (Приволжский) федеральный университет»; ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России
Email: alinayakupova96@yandex.ru
ORCID iD: 0000-0001-9542-3580
к.м.н., доц., зав. каф. фундаментальных основ клинической медицины Института фундаментальной медицины и биологии ФГАОУ ВО КФУ, каф. госпитальной терапии ФГБОУ ВО КГМУ
Россия, КазаньАйрат Габбасович Сафин
ФГАОУ ВО «Казанский (Приволжский) федеральный университет»
Email: alinayakupova96@yandex.ru
ORCID iD: 0000-0002-4689-7058
зав. эндоскопическим отд-нием Медико-санитарной части ФГАОУ ВО КФУ
Россия, КазаньИльмира Марсовна Алиева
ФГАОУ ВО «Казанский (Приволжский) федеральный университет»
Email: alinayakupova96@yandex.ru
ORCID iD: 0000-0001-5067-5848
к.м.н., врач-эндоскопист Медико-санитарной части ФГАОУ ВО КФУ
Россия, КазаньЮлия Владимировна Ослопова
ФГАОУ ВО «Казанский (Приволжский) федеральный университет»
Email: alinayakupova96@yandex.ru
ORCID iD: 0000-0002-9752-8703
к.м.н., доц., доц. каф. фундаментальных основ клинической медицины Института фундаментальной медицины и биологии ФГАОУ ВО КФУ
Россия, КазаньРустам Аббасович Абдулхаков
ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России
Email: alinayakupova96@yandex.ru
ORCID iD: 0000-0002-1509-6776
д.м.н., проф., проф. каф. госпитальной терапии ФГБОУ ВО КГМУ
Россия, КазаньСписок литературы
- Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-80. doi: 10.1136/gutjnl-2016-313017
- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-15. doi: 10.1056/NEJMoa1205037
- Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142-9. doi: 10.1001/jama.2015.18098
- Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection. Ann Intern Med. 2016;165:609-16. doi: 10.7326/M16-0271
- Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835-43. doi: 10.1111/apt.13144
- Hvas CL, Dahl Jorgensen SM, Jorgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019;156:1324-32. doi: 10.1053/j.gastro.2018
- Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection. JAMA. 2017;318:1985-93. doi: 10.1001/jama.2017
- Cammarota G, Ianiro G, Magalini S, et al. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015;163:487-8. doi: 10.7326/L15-5139
- Fischer M, Sipe B, Cheng Y-W, et al. Fecal microbiota transplant in severe and severe complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8:289-302. doi: 10.1080/19490976.2016.1273998
- Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470-6. doi: 10.1111/apt.13290
- Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013;47:735-7. doi: 10.1097/MCG.0b013e31829004ae
- Ianiro G, Masucci L, Quaranta G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions. Aliment Pharmacol Ther. 2018;48:152-9. doi: 10.1111/apt.14816
- Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:102-9. doi: 10.1053/j.gastro.2015.04.001
- Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis. JAMA. 2019;321:156-64. doi: 10.1001/jama.2018.20046
- Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomized placebo controlled trial. Lancet. 2017;389:1218-28. doi: 10.1016/S0140-6736(17)30182-4
- Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-8. doi: 10.1053/j.gastro.2015.03.045
- Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46:213-24. doi: 10.1111/apt.14173
- Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23:1702-9. doi: 10.1097/MIB.0000000000001228
- Scaldaferri F, Pecere S, Petito V, et al. Efficacy and mechanisms of action of fecal microbiota transplantation in ulcerative colitis: pitfalls and promises from a first meta-analysis. Transplant Proc. 2016;48:402-7. doi: 10.1016/j.transproceed.2015.12.040
- Ianiro G, Bibbò S, Scaldaferri F, et al. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore). 2014;93(19):97. doi: 10.1097/MD.0000000000000097
- Sood A, Mahajan R, Singh A, et al. Role of faecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019;13(10):1311-7. doi: 10.1093/ecco-jcc/jjz060
- Щербаков П.Л., Белова Н.Д., Генерозов Э.В. и др. Применение фекальной трансплантации в лечении заболеваний пищеварительного тракта (первый клинический опыт). Доктор.Ру. 2019;3(158):40-6 [Scherbakov PL, Belova ND, Generozov EV, et al. Faecal Transplant in GIT Treatment (Pilot Clinical Experience). Doctor.Ru. 2019;3(158):40-6 (In Russ.)]. doi: 10.31550/1727-2378-2019-158-3-40-46
- Halkjaer SI, Christensen AH, Lo BZ, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomized, double-blind placebo-controlled study. Gut. 2018;67(12):2107-15. doi: 10.1136/gutjnl-2018-316434
- Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized, placebo-controlled, parallel-group, single-center trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. doi: 10.1016/S2468-1253(17)30338-2
- Holster S, Lindqvist CM, Repsilber D, et al. The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome. Clin Transl Gastroenterol. 2019;10(4):e00034. doi: 10.14309/ctg.0000000000000034
- Ianiro G, Eusebi LH, Black CJ, et al. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50:240-8. doi: 10.1111/apt.15330
- Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66(6):1727-38. doi: 10.1002/hep.29306
- Bajaj JS, Kakiyama G, Savidge T, et al. Antibiotic‐associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant. Hepatology. 2018;68:1549-58. doi: 10.1002/hep.30037
- Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143:913-6. doi: 10.1053/j.gastro.2012.06.031
- Kootte RS, Levin E, Salojarvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611-9. doi: 10.1016/j.cmet.2017.09.008
- Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic resistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017;65:364-70. doi: 10.1093/cid/cix252
- Huttner BD, de Lastours V, Wassenberg M, et al. A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin Microbiol Infect. 2019;25:830-8. doi: 10.1016/j.cmi.2018.12.009
- Kuijper EJ, Vendrik KEW, Vehreschild MJGT. Manipulation of the microbiota to eradicate multidrug-resistant Enterobacteriaceae from the human intestinal tract. Clin Microbiol Infect. 2019;25:786-9. doi: 10.1016/j.cmi.2019.03.025
- Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2019;114:1071-9. doi: 10.14309/ajg.0000000000000115
- Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5. doi: 10.1186/s40168-016-0225-7
- Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24:1804-8. doi: 10.1038/s41591-018-0238-9
- Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91-7. doi: 10.1126/science.aan3706
- Youlian Z, Haoming X, Hongli H, et al. Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders? Hindawi BioMed Res Int Vol. 2019;1-11. doi: 10.1155.2019.3469754
- Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. Clin Microbiol Inf. 2017;23(12):924-30. doi: 10.1016/j.cmi.2017.05.015
- Mullish BH, Quraishi M, Segal J, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;0:1-22. doi: 10.1136/gutjnl-2018-316818
- Kump P, Krause R, Steininger C, et al. Empfehlungenzur Anwendung der fäkalen Mikrobiotatransplantation „Stuhltransplantation“: Konsensus der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) in Zusammenarbeitmit der Österreichischen Gesellschaftfür Infektiologie und Tropenmedizin (OEGIT). Z Gastroenterol. 2014;52:1485-92. doi: 10.1055/s-0034-1385562
- Cammarota G, Ianiro G, Kelly CR, Mullish BH, et al. International consensus conference on stool banking for faecalmicrobiota transplantation in clinical practice. Gut. 2019;68:2111-21. doi: 10.1136/gutjnl-2019-319548
- OpenBiome. OpenBiome Quality Metrics. 2019. Available at: https://static1.squarespace.com/static/50e0c29ae4b0a05702af7e6a/t/
- cc2477b36a72a000152b793/1556236156464/Quality+Metrics.pdf
- Kassam Z, Dubois NE, Ling K. 512 – donor health screening for fecal microbiota transplantation: prospective evaluation of 15,317 candidate donors. Gastroenterology. 2019;156:100-1. doi: 10.1016/S0016-5085(19)37042-8
- Paramsothy S, Borody TJ, Lin E, et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015;21:1600-6. doi: 10.1097/MIB.0000000000000405
- Food and Drug Administration. Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation – screening and testing of stool donors for multi-drug resistant organisms. 2019. Available at: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-additional-safety-protections-regarding-use-fecal-microbiota-transplantation
- Chu ND, Smith MB, Perrotta AR, et al. Profiling living bacteria informs preparation of fecal microbiota transplantations. PLoS One. 2017. 26;12(1):e0170922. doi: 10.1371/journal.pone.0170922
- Satokari R, Mattila E, Kainulainen V, Arkkila PE. Simple faecal preparation and efficacy of frozen inoculum in faecalmicrobiota transplantation for recurrent Clostridium difficile infection – an observational cohort study. Aliment Pharmacol Ther. 2015;41:46-53. doi: 10.1111/apt.13009
- Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490-6. doi: 10.1053/j.gastro.2011.11.037
- Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515-22. doi: 10.1093/cid/ciu135
- Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 2015;42:1011-8. doi: 10.1111/apt.13366
- Adair A, Wigmore SJ. Paid organ donation: the case against. Annals. 2011;93:191-2. doi: 10.1308/147870811X565061a
- Elliott RJ, Nienga M, Ladha A, et al. Stool processing speed and storage duration do not impact clinical effectiveness of fecal microbiota transplantation across 1,924 Clostridium difficile infection patients. Am J Gastroenterol. 2016;111. doi: 10.14309/00000434-201610001-00119
- Budree S, Elliott RJ, Rao S, et al. Donor stool processing time: the effect on the intestinal microbiome and clinical outcomes of fecal microbiota transplantation in Clostridium difficile infection. Gastroenterology. 2017;152:1006. doi: 10.1016/S0016-5085(17)33415-7
- Bahl MI, Bergström A, Licht TR. Freezing fecal samples prior to DNA extraction affects the Firmicutes to Bacteroidetes ratio determined by downstream quantitative PCR analysis. FEMS Microbiol Lett. 2012;329:193-7. doi: 10.1111/j.1574-6968.2012.02523.x
- Sleight SC, Wigginton NS, Lenski RE. Increased susceptibility to repeated freeze-thaw cycles in Escherichia coli following long-term evolution in a benign environment. BMC Evol Biol. 2006;6:104. doi: 10.1186/1471-2148-6-104
- Long C, Yu Y, Cui B, et al. A novel quick transendoscopic enteral tubing in mid-gut: technique and training with video. BMC Gastroenterol.2018;18:37. doi: 10.1186/s12876-018-0766-2
- Shi Y, Dong Y, Huang W, et al. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. Public Library of Science ONE. 2016:11(6):e0157259. doi: 10.1371/ journal.pone.0157259
- Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open. 2016, 4: 610-3. doi: 10.1055/s-0042-105205
- Osman M, O’Brien K, Stoltzner Z, et al. Safety and efficacy of fecal microbiota transplantation for recurrent Clostridium difficile infection from an international public stool bank: results from a 2050-patient multicenter cohort. Open Forum Infect Dis. 2016;3. doi: 10.1093/ofid/ofw172.1668
- Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500-8. doi: 10.1038/ajg.2013.59
- Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014;48:693-702. doi: 10.1097/MCG.0000000000000046